In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs; development of potential pharmaceutical
products including NUVIGIL for the treatment of schizophrenia;
interpretation of clinical results; prospects for regulatory approval,
including with respect to TREANDA and NUVIGIL; manufacturing development
and capabilities; market prospects for its products; sales, adjusted net
income and basic adjusted income per common share guidance for the first
quarter and full-year 2008; and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other words
and terms of similar meaning. Cephalon's performance and financial results
could differ materially from those reflected in these forward-looking
statements due to general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical industries as
well as more specific risks and uncertainties facing Cephalon such as those
set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Given these risks and uncertainties,
any or all of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward- looking
statements. Furthermore, Cephalon does not intend to update publicly any
forward-looking statement, except as required by law.
|SOURCE Cephalon, Inc.|
Copyright©2008 PR Newswire.
All rights reserved